FundedIQ
Biotechnology

Regenosine: Funding, Investors & Team (Sep 2026)

a privately held corporation specialising in the creation and promotion of world-class regenerative treatments for osteoarthritis Our patented platform technology taps into the purinergic system's capacity for healing, which is essential for preserving the homeostasis of cartilage. Our flagship product, which targets the rapidly expanding joint preservation industry, is a patented formulation for regenerating cartilage in joints with established osteoarthritis. Our objective is to provide patients with a disease-modifying therapy with uncompromised efficacy in comparison to currently available technology. We will considerably enhance clinical results and patient quality of life by creating this disease-modifying medication, and we will lower the overall costs of regenerative medicine-related health care delivery.

regenosine.com LinkedIn New Jersey, Trinidad and Tobago 11-50 employees
Total raised
$30k
Rounds
1
Latest
Undisclosed round
Feb 2023

Regenosine has raised $30k across 1 funding round on record, the most recent an undisclosed round of $30k announced in Feb 2023.

That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Regenosine Company Profile and Key Stats

Total funding raised
$30k
across 1 round on record
Funding rounds on record
1
Latest funding round
Undisclosed round
$30k in Feb 2023
Employees
11-50
reported band
Headquarters
New Jersey, Trinidad and Tobago

Latest funding round on record: Feb 2023.

Regenosine Funding Rounds

Date
Round
Amount
Undisclosed round
$30k

Regenosine Founders and Leadership Team

Name
Role
Contact
Sid Angle
CEO
Locked

Contact details for the Regenosine team: 1 of 1 has an email address on file.

Start 14-day free trial →

Regenosine Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round

Regenosine's latest round of $30k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Regenosine in Biotechnology and New Jersey

Companies Similar to Regenosine

Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…

Series E $92.5M

Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…

Series B $40.0M

Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…

Private Equity

An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…

Undisclosed round $1.8M

Shennon Biotechnologies conducts a thorough examination and control of an enormous quantity of cells,…

Undisclosed round $12.0M

Artcline is a biotech company that creates diagnostic and therapeutic techniques for critical care medicine.

Private Equity $3.9M

Connecta Therapeutics is a biotechnology company that develops new treatments for unresolved medical needs of…

Undisclosed round $4.2M

SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…

Undisclosed round $960k

DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…

Series B $4.0M

Solstice Oncology is a clinical stage immuno-oncology company

Series A $225M

Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…

Series F $275M

ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…

Undisclosed round $23.3M

Regenosine Funding FAQs

What does Regenosine do?

a privately held corporation specialising in the creation and promotion of world-class regenerative treatments for osteoarthritis Our patented platform technology taps into the purinergic system's capacity for healing, which is essential for preserving the homeostasis of cartilage. Our flagship product, which targets the rapidly expanding joint preservation industry, is a patented formulation for regenerating cartilage in joints with established osteoarthritis. Our objective is to provide patients with a disease-modifying therapy with uncompromised efficacy in comparison to currently available technology. We will considerably enhance clinical results and patient quality of life by creating this disease-modifying medication, and we will lower the overall costs of regenerative medicine-related health care delivery.

How much funding has Regenosine raised?

Regenosine has raised $30k across 1 round on record. The most recent is an undisclosed round of $30k announced in Feb 2023.

When did Regenosine last raise funding?

Regenosine's most recent funding round on record is an undisclosed round of $30k, announced in Feb 2023.

Who is the CEO of Regenosine?

Sid Angle is listed as CEO at Regenosine.

Where is Regenosine headquartered?

Regenosine is based in New Jersey, Saint Patrick, Trinidad and Tobago.

How many employees does Regenosine have?

Regenosine is in the 11-50 employee band.

How does Regenosine's funding compare to other Biotechnology startups?

Regenosine's latest round of $30k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.

About FundedIQ's Regenosine Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Regenosine is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.